The record
Written from the 1 report below. Nothing here is unsourced.
- Sai Life Sciences is expanding its production capacity and entering the fields of peptides and formulations.
- The expansion aligns with a broader industry trend of global pharmaceutical companies reducing reliance on China for supply chains.
- The company anticipates higher revenue growth for the second half of the 2027 fiscal year.
- Strategic scaling allows the firm to capture more market share in the contract research, development, and manufacturing organization sector.
Coverage1
1 report
English national1
All filed from India
Named India · China · Sai Life Sciences
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.